We suggest that ASA (81 mg/day) be prescribed for patients with none of the risks outlined in the “CCS algorithm” (age <65 years and no CHADS2 risk factors) who have arterial disease (coronary, aortic, or peripheral). (Conditional Recommendation, Moderate Quality Evidence)